This performance reflects accelerating demand for high-efficacy, multi-indication GLP-1 molecules across North America, Europe, and Asia-Pacific, driven by blockbuster drugs such as semaglutide and tirzepatide
8 Small amounts of GLP-1 may also be produced by preproglucagon neurons, located in the nucleus tractus solitarii of the brainstem 26,27 and projected to other brain regions, such as the nuclei of the hypothalamus, including the arcuate and paraventricular nuclei
in adolescents, the concern shifts to premature growth plate closure or abnormal skeletal proportioning, though this has not been studied for ipamorelin specifically [10]
However, several important considerations must be addressed
Church DD, Hirsch KR, Park S, et al
This article explains the evidence around stopping GLP-1 therapy, what to expect when treatment ends, and how to discontinue safely under medical supervision in line with UK clinical guidance